SDIC Securities released a research report on April 9 stating that it gave Keqian Biotech (688526.SH) a purchase rating. The main reasons for the rating include: 1) performance overview: Q4 performance is under pressure, and credit impairment is dragging down profit levels; 2) the main pig breeding business is stable, and the poultry seedlings business continues to expand; 3) R&D lays the future, and there are sufficient reserves of new products. (Mainichi Keizai Shimbun)
国投证券4月9日发布研报称，给予科前生物（688526.SH）买入评级。评级理由主要包括：1）业绩概况：Q4业绩承压，信用减值拖累利润水平；2）主业猪苗持稳，禽苗业务持续放量；3）研发奠定未来，新品储备充足。（每日经济新闻）
SDIC Securities released a research report on April 9 stating that it gave Keqian Biotech (688526.SH) a purchase rating. The main reasons for the rating include: 1) performance overview: Q4 performance is under pressure, and credit impairment is dragging
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.